secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-208095
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q2 2023: cash $176.3M; IND cleared for CABA-201 in myositis
-------------------------------------------------------------------------

- Cash, equivalents & investments of $176.3M as of June 30, 2023, extending runway into Q4 2025.
- Net proceeds of ~$93.8M from May 2023 public offering of 8,337,500 shares at $12.00/share.
- R&D expenses $11.8M (Q2 2023) vs $9.5M (Q2 2022); G&A $4.1M vs $3.5M.
- FDA cleared second IND for CABA-201 in myositis; Fast Track designation granted for SLE/LN.
- Anticipates initial 3-month clinical data for CABA-201 by first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/0001193125-23-208095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/d538476d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-208095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer